TB-500 is a synthetic peptide based on thymosin beta-4 (Tβ4), a 43-amino-acid protein found naturally in almost every human and animal cell, with especially high concentrations in wound fluid and blood platelets. Products sold as "TB-500" are generally either the full synthetic protein or, more commonly, a shorter synthetic fragment containing its active region — the segment responsible for binding actin.

The plain-English mechanism: thymosin beta-4's day job in the cell is managing actin, the protein cells use to build their internal skeleton and to move. By binding and releasing actin, Tβ4 helps cells migrate — and cell migration is a core step in wound repair, when new cells must move into damaged tissue. In laboratory and animal studies, Tβ4 has been associated with faster wound closure, new blood-vessel growth, reduced inflammation, and less scar formation. As with BPC-157, these mechanisms are well described in cells and animals and unproven as therapeutic effects in humans.

Regulatory status: TB-500 is not approved by the FDA or any major regulator for human use. Its name actually comes from the veterinary world — it was marketed for racehorses — and human-grade approval has never followed. A pharmaceutical version of thymosin beta-4 (developed under names like RGN-259 for eye conditions) has been through early clinical trials without reaching approval. The FDA has included thymosin beta-4 among substances raising significant safety concerns for use in compounding, and WADA prohibits TB-500 and thymosin beta-4 in sport at all times.

The evidence base for TB-500/thymosin beta-4 is stronger on mechanism than on outcomes, and overwhelmingly preclinical:

• Animal wound models: faster dermal wound closure in rats and mice, including in diabetic and steroid-impaired healing models;
• Cardiac studies: in rodent heart-attack models, Tβ4 improved cardiomyocyte survival and cardiac function — among the most cited findings in the literature;
• Corneal injury models: improved epithelial healing, which motivated the human eye-drop trials;
• Human trials: small early-phase studies of pharmaceutical Tβ4 eye drops (RGN-259) for dry eye and neurotrophic keratopathy, and a phase 1 safety study of intravenous Tβ4, which reported no serious short-term safety signals at studied doses but was not designed to prove efficacy.

What does not exist: any published randomized controlled trial showing that injected TB-500 improves muscle, tendon, or joint healing in humans — the use it is most commonly discussed for online. The leap from rodent cardiac and dermal models to human orthopedic recovery is exactly that: a leap.

It is also worth noting that the gray-market product is not the pharmaceutical article. Trials of RGN-259 used pharmaceutical-grade material under clinical oversight; a vial bought online has no such provenance.

The compound's history explains some of the mismatch between its reputation and its evidence. TB-500 first became notorious in horse racing, where trainers used it in the hope of speeding recovery in racehorses and where several doping cases were prosecuted. That equine notoriety migrated to human fitness circles more or less intact — carrying the assumption of efficacy with it, without the human trials ever being run.

TB-500 has no controlled human safety dataset for the injected, repeated-use pattern discussed online. The primary risk is therefore the unknown: no data on long-term effects, interactions, or safe exposure levels in humans.

Concerns worth stating explicitly:

• Theoretical proliferation concerns — thymosin beta-4 promotes cell migration and blood-vessel growth, and its biology intersects with pathways studied in cancer research; whether exogenous use poses tumor-related risk in humans is simply unknown, in either direction;
• FDA compounding concerns — regulators have flagged thymosin-related peptides among substances lacking adequate human safety data for compounded use;
• Gray-market purity risk — independent analyses of research-chemical peptides have found mislabeled content, impurities, and endotoxin contamination; injecting such products adds infection and immune-reaction risk;
• Anecdotal reports of fatigue, headache, or injection-site reactions are unverified and unquantified;
• Anti-doping: TB-500 is explicitly prohibited by WADA, and detection methods exist — positive tests have ended careers in several sports.

As throughout this site: any decision involving TB-500 is one to bring to a licensed clinician, along with the honest fact that human data is minimal.

There is no established human dose of TB-500. No human dose-finding or efficacy trials of injected TB-500 have been published, so every dosing figure circulating online is anecdotal convention, not evidence.

What the literature actually contains:

• Animal studies used a wide range of doses and routes (topical, intraperitoneal, intravenous) depending on the injury model — there is no single canonical animal dose to point to;
• The phase 1 human safety study of intravenous pharmaceutical Tβ4 tested ascending single and repeated doses (roughly 42 to 1,260 mg total exposure across regimens) purely to assess short-term safety, not efficacy — and this pharmaceutical context does not translate to gray-market products;
• Online self-experimenter convention commonly references multi-milligram weekly amounts in a "loading then maintenance" pattern — a structure with no published clinical basis whatsoever.

The honest summary: studies in animals used model-specific doses, one small human safety trial tested pharmaceutical material under medical supervision, and no validated human dosing exists. Nothing here is a recommendation.

TB-500's reported half-life is on the order of 60 hours — about two and a half days — considerably longer than short-acting peptides like BPC-157 but far shorter than weekly GLP-1 drugs. A compound with a ~60-hour half-life takes roughly 12 days (five half-lives) to substantially clear after a final dose, and with repeated dosing, levels accumulate for about two weeks before flattening.

The scheduling implication is that doses spaced a few days apart overlap meaningfully: each new dose lands on residual compound from previous ones. This is presumably why gray-market convention gravitates to less-than-daily patterns — though, to repeat, that convention is not evidence-based.

A concrete illustration: suppose equal doses are logged on Monday, Thursday, and Sunday. By the following Wednesday, the Monday dose has been through roughly four half-lives (about 6% remains), Thursday's through about two and a half (roughly 18%), and Sunday's through one (50%) — so the total on board is a sum of three different decay states. No one carries that arithmetic in their head reliably.

For tracking purposes, mid-length half-lives are where mental math fails hardest: the level at any moment depends on several prior doses, each partially decayed. A log with timestamps does that arithmetic honestly.